These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2110815

  • 21. Mechanism of oncogenicity for bioreductive drugs.
    Hei TK, Piao CQ, He ZY, Hall EJ.
    Int J Radiat Oncol Biol Phys; 1992; 22(4):747-50. PubMed ID: 1544847
    [Abstract] [Full Text] [Related]

  • 22. Variation of the radiosensitizing efficiency of RSU-1069 with pre-irradiation contact times: a rapid mix study.
    Austen KR, Jenner TJ, O'Neill P, Fielden EM.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1987 Aug; 52(2):281-8. PubMed ID: 3497125
    [Abstract] [Full Text] [Related]

  • 23. Mechanisms of hypoxic and aerobic cytotoxicity of mitomycin C in Chinese hamster V79 cells.
    Krishna MC, DeGraff W, Tamura S, Gonzalez FJ, Samuni A, Russo A, Mitchell JB.
    Cancer Res; 1991 Dec 15; 51(24):6622-8. PubMed ID: 1660344
    [Abstract] [Full Text] [Related]

  • 24. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
    Walling J, Stratford IJ, Adams GE, Stephens MA.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Apr 15; 53(4):641-9. PubMed ID: 3258298
    [Abstract] [Full Text] [Related]

  • 25. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells.
    Marshall RS, Rauth AM.
    Cancer Res; 1988 Oct 15; 48(20):5655-9. PubMed ID: 3167822
    [Abstract] [Full Text] [Related]

  • 26. Radiosensitizing and cytotoxic effects of nitroimidazoles in CHO cells expressing elevated levels of glutathione-S-transferase.
    Stratford IJ, Hickson ID, Robson CN, Stephens M.
    Int J Radiat Oncol Biol Phys; 1989 May 15; 16(5):1307-10. PubMed ID: 2523884
    [Abstract] [Full Text] [Related]

  • 27. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
    Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ.
    Br J Cancer; 2000 Feb 15; 82(3):651-6. PubMed ID: 10682679
    [Abstract] [Full Text] [Related]

  • 28. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
    Hill RP, Gulyas S, Whitmore GF.
    Br J Cancer; 1986 Jun 15; 53(6):743-51. PubMed ID: 3755053
    [Abstract] [Full Text] [Related]

  • 29. The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.
    Skarsgard LD, Skwarchuk MW, Vinczan A, Chaplin DJ.
    Br J Cancer; 1993 Oct 15; 68(4):681-3. PubMed ID: 8398693
    [Abstract] [Full Text] [Related]

  • 30. DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH.
    Tocher JH, Virk NS, Edwards DI.
    Biochem Pharmacol; 1990 Sep 15; 40(6):1405-10. PubMed ID: 2144963
    [Abstract] [Full Text] [Related]

  • 31. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
    Stratford IJ, Walling JM, Silver AR.
    Br J Cancer; 1986 Mar 15; 53(3):339-44. PubMed ID: 3754453
    [Abstract] [Full Text] [Related]

  • 32. Bioreductive therapies: an overview of drugs and their mechanisms of action.
    Rauth AM, Melo T, Misra V.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):755-62. PubMed ID: 9845091
    [Abstract] [Full Text] [Related]

  • 33. The repair of DNA damage induced in V79 mammalian cells by the nitroimidazole-aziridine, RSU-1069. Implications for radiosensitization.
    Jenner TJ, O'Neill P, Crump PW, Fielden EM, Sapora O, Santodonato L.
    Biochem Pharmacol; 1991 Oct 09; 42(9):1705-10. PubMed ID: 1930296
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions.
    Marshall RS, Paterson MC, Rauth AM.
    Br J Cancer; 1989 Mar 09; 59(3):341-6. PubMed ID: 2467684
    [Abstract] [Full Text] [Related]

  • 36. Bioreductive drugs: from concept to clinic.
    McKeown SR, Cowen RL, Williams KJ.
    Clin Oncol (R Coll Radiol); 2007 Aug 09; 19(6):427-42. PubMed ID: 17482438
    [Abstract] [Full Text] [Related]

  • 37. The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts.
    Egelmeers A, Dirix LY, Lyczek J, De Bruijn EA, Van Oosterom AT, Scalliet P.
    Anticancer Drugs; 1996 Jul 09; 7(5):586-90. PubMed ID: 8862727
    [Abstract] [Full Text] [Related]

  • 38. Hypoxic cells as specific drug targets for chemotherapy.
    Kennedy KA.
    Anticancer Drug Des; 1987 Oct 09; 2(2):181-94. PubMed ID: 3130070
    [Abstract] [Full Text] [Related]

  • 39. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
    Lartigau E, Stern S, Guichard M.
    Cancer Radiother; 2000 Oct 09; 4(3):217-22. PubMed ID: 10897765
    [Abstract] [Full Text] [Related]

  • 40. Bioreduction of RSU 1069 and mitomycin C after dearterialization.
    Wang LQ, Persson BG, Bengmark S.
    Eur J Surg Oncol; 1993 Oct 09; 19(5):455-62. PubMed ID: 8405482
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.